Prostatic Size Reduction Following of Leuprorelin Acetate

NCT06184464 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-09-19

No results posted yet for this study

Summary

To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.

Conditions

  • Prostate Cancer Adenocarcinoma
  • Prostate Adenocarcinoma

Interventions

OTHER

ACETATE LEUPRELINE

USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION

Sponsors & Collaborators

  • Consorci Sanitari de Terrassa

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2024-12-15
Completion
2024-12-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06184464 on ClinicalTrials.gov